Avenue Therapeutics, Inc. Gains 37.04%
Fri, Oct 14, 2022 at 09:06 PM
Avenue Therapeutics, Inc. (ATXI:NASDAQ) soared at $3.33, a gain of 37%. The stock appeared on our News Catalysts scanner on Wed, Oct 12, 2022 at 01:05 PM in the 'PUBLIC OFFERING' category. From Fri, Sep 30, 2022, the stock recorded 40.00% Up Days and 36.36% Green Days
The stock spiked on Tue, Oct 04, 2022 at $16.65 with a volume of 10M+.
About Avenue Therapeutics, Inc. (ATXI:NASDAQ)
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of an intravenous, or IV, formulation of tramadol HCl, or IV Tramadol, for the management of moderate to moderately severe postoperative pain.
Top 10 Gainers:
- Creatd Inc. (CRTD:NASDAQ), 69.57%
- Agrify Corporation (AGFY:NASDAQ), 53.75%
- FedNat Holding Company (FNHC:NASDAQ), 48.02%
- IMARA Inc. (IMRA:NASDAQ), 46.9%
- Avenue Therapeutics, Inc. (ATXI:NASDAQ), 37.04%
- MicroCloud Hologram Inc. (HOLO:NASDAQ), 27.72%
- Gravitas Education Holdings Inc ADR (GEHI:NYSE), 27.07%
- Marker Therapeutics, Inc. (MRKR:NASDAQ), 25.81%
- Nutanix, Inc. (NTNX:NASDAQ), 24.59%
- Intelligent Living Application Group Inc. (ILAG:NASDAQ), 23.76%